Emerging Onychomycosis Treatment Market Trends: Increasing Focus On Innovative Product Approval To Gain A Competitive Edge Shaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Onychomycosis Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for onychomycosis treatment has seen robust growth in the latter years. There's a projection for an increase from $3.65 billion in 2024 to $3.92 billion in 2025, marking a compound annual growth rate (CAGR) of 7.4%. The surge in its historical period can be credited to several factors such as surge in fungal infections, an aging demographic, increased public awareness, escalating occurrence of onychomycosis, and enhanced disposable incomes.

How Will the Onychomycosis Treatment Market Size Evolve and Grow by 2029?
The market size for onychomycosis treatment is anticipated to experience substantial growth in the coming years. It is projected to expand to $5.09 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. The predicted growth in this period can be due to several factors including the growing elderly population, telemedicine progress, combined therapies, enhanced access to medical care, evolving lifestyles, environmental causes, and a growing incidence of diabetes. Key trends for the forecast period encompass advancements in dermatology, innovative drug delivery systems, individually tailored treatment plans, developments in topical treatments, digital health solutions, and laser therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What Drivers Are Propelling the Growth of Onychomycosis Treatment Market Forward?
Growing fungal infections are anticipated to stimulate the expansion of the market for onychomycosis treatment. These microbial ailments are created by various fungi, which can impact multiple body parts or instigate specific conditions. Onychomycosis, a fungus affecting nails, is generally cured with oral antifungal drugs or antifungal topical solutions to eliminate the underlying fungus and provoke healthy nail growth. For instance, the UK Health Security Agency reported 2,265 yeast-induced bloodstream infection cases in England in 2022 in September 2023. The infection rate due to yeast slightly increased to 4.0 per 100,000 people from 3.8 per 100,000 in 2021. The most frequently identified yeast species in blood samples were Candida albicans (40%), Nakaseomyces glabratus (formerly Candida glabrata, 29%), and Candida parapsilosis (13%). This escalation in fungal infections is thus spurring the expansion of the onychomycosis treatment market. The increasingly common occurrence of diabetes is predicted to boost the progress of the onychomycosis treatment market. Diabetes, a persistent ailment characterized by high blood glucose levels, heightens the probability of contracting onychomycosis, amplifies infection risk, and delays the healing process. Topical and laser treatments can help circumvent complications and enhance foot health, reducing risks of future infections. For instance, Diabetes UK reported in May 2024 that around 4.4 million people in the UK had been diagnosed with diabetes during 2022-23. Of these cases, nearly 8% were type 1 diabetes while type 2 diabetes made up approximately 90%. The remaining 2% comprised other less frequent types of diabetes. Hence, the growing prevalence of diabetes is contributing to the progress of the onychomycosis treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

Which Emerging Trends Are Transforming the Onychomycosis Treatment Market in 2025?
Leading businesses in the onychomycosis treatment sector are prioritizing the development and approval of innovative products such as MOB-015, as a way to enhance their market position. Notably, Moberg Pharma AB, a pharmaceutical company based in Sweden, obtained approval in June 2023 for MOB-015 from the European Union. The medication, designed to treat mild to moderate fungal nail infections in adults, secured its first worldwide marketing authorization with this approval. Evidence from two Phase 3 trials supported this authorization as they showed that MOB-015 had an improved mycological cure rate (76% compared to up to 42% for comparators) and a much higher overall cure rate than the vehicle. This was achieved without any serious side effects. MOB-015, a topical terbinafine formulation, delivers effective amounts of terbinafine to the nail and nail bed devoid of the systemic exposure risks linked with oral terbinafine treatment.

What Are the Key Segments in the Onychomycosis Treatment Market?
The onychomycosis treatment market covered in this report is segmented -

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types
2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy
3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

Who Are the Key Players Shaping the Onychomycosis Treatment Market's Competitive Landscape?
Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

What Geographic Markets Are Powering Growth in the Onychomycosis Treatment Market?
North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.